Spinal Cord Injury Model Systems (SCIMS) - Education Module
Launched by UNIVERSITY OF MIAMI · Aug 16, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Spinal Cord Injury Model Systems (SCIMS) study is looking to understand if education about the health risks related to obesity and cardiometabolic diseases can help people with spinal cord injuries (SCI) improve their health. The goal is to see if learning about these risks can help participants better manage their health after their injury.
To participate in this study, you should be between 18 and 70 years old, have a spinal cord injury classified as complete or incomplete (levels C5 and below), and have been discharged from rehabilitation within the last four months. Unfortunately, if you are pregnant, have serious cognitive issues that might affect your ability to give consent, have severe pressure injuries, or are currently incarcerated, you won't be eligible to join. If you decide to participate, you can expect to receive important information that could help you understand and manage your health risks better.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Men and Women with SCI/D aged 18-70 years.
- • 2. Neurologically complete and incomplete American Spinal Injury Association (ASIA) Impairment scale (AIS) A-D spinal cord levels C5 and below.
- • 3. Enrolled no later than 4 months following discharge from initial rehabilitation from SCI.
- Exclusion Criteria:
- • 1. Pregnancy determined by urine testing in sexually active females.
- • 2. Cognitive impairment that compromises the legitimacy of consent.
- • 3. Grade 3-4 pressure injury at the time of study entry.
- • 4. Prisoners
About University Of Miami
The University of Miami, a leading academic institution, is dedicated to advancing medical research and improving patient care through innovative clinical trials. With a commitment to excellence in education and research, the university fosters collaboration among multidisciplinary teams to explore new therapies and treatment modalities. Its extensive clinical programs are supported by state-of-the-art facilities and a diverse patient population, enabling the exploration of cutting-edge solutions to complex health challenges. The University of Miami is poised to contribute significantly to the field of medicine through its rigorous scientific inquiry and a steadfast commitment to ethical research practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Washington, District Of Columbia, United States
Miami, Florida, United States
Minneapolis, Minnesota, United States
Dallas, Texas, United States
Richmond, Virginia, United States
Patients applied
Trial Officials
Gary Farkas, PhD
Principal Investigator
University of Miami
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported